Skip to content

Committee Composition

Board of Directors Audit & Finance Leadership & Compensation Nominating & Corporate Governance Science & Innovation
Felix J. Baker Ph.D.
Director

Felix J. Baker, Ph.D., has been a director of Alexion since June 2015. Dr. Baker is a Co-Managing Member of Baker Bros. Advisors LP, an investment advisor focused on investments in life science and biotechnology companies. Dr. Baker and his brother, Julian Baker, started their fund-management careers in 1994 when they co-founded a biotechnology investing partnership with the Tisch Family. Dr. Baker currently serves on the Board of Directors at Genomic Health, Inc. and Seattle Genetics, Inc. and previously served on the Board of Directors at Synageva BioPharma Corp. and Ardea Bioscience, Inc.

Dr. Baker holds a Bachelor of Science and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school.

Dr. Baker is Chair of the Science and Innovation Committee and a member of the Nominating and Corporate Governance Committee.

   
David R. Brennan
Chairman

David R. Brennan is Chairman of Alexion’s Board of Directors. He served as a Director of Alexion since July 2014 and as Interim Chief Executive Officer of Alexion from December 2016 to March 2017.

From 2006 to 2012, he served as Chief Executive Officer and Executive Director of AstraZeneca PLC, one of the world's largest pharmaceutical companies. Mr. Brennan worked for AstraZeneca in increasing roles of responsibility, including as Executive Vice President of North America from 2001 to 2006, and as Senior Vice President of Commercialization and Portfolio Management from 1999 to 2001.

Prior to the merger of Astra AB and Zeneca Plc, he served as Senior Vice President of Business Planning and Development of Astra Pharmaceuticals LP, the American subsidiary of Astra AB. Mr. Brennan began his career in 1975 at Merck and Co. Inc., where he rose from Sales Representative in the U.S. Division to General Manager of Chibret International, a French subsidiary of Merck.

Mr. Brennan currently serves on the Board of Directors Insmed Incorporated, and previously served on the Board of Directors of AstraZeneca PLC, Innocol, Inc., Reed Elsevier PLC, and the Pharmaceutical Research & Manufacturers of America (PhRMA).

Mr. Brennan received a Bachelor of Arts in business administration from Gettysburg College, where he is a member of the Board of Trustees.

Mr. Brennan is a member of the Science and Innovation Committee.

   
Christopher J. Coughlin
Director

Christopher J. Coughlin has been a director of Alexion since July 2014. He served as Advisor to the Chairman and CEO of Tyco International Ltd., a global provider of diversified products, services and industries, from 2010 to 2012, and as Executive Vice President and Chief Financial Officer of Tyco from 2005 to 2010 and during a period of significant international growth and restructuring. Mr. Coughlin previously served at the Interpublic Group of Companies, Inc. as Executive Vice President, Chief Operating Officer from 2003 to 2004. From 1998 to 2003, he served as Executive Vice President and Chief Financial Officer of Pharmacia Corporation. From 1997 to 1998 he was President, International at Nabisco Group Holdings and from 1996 to 1997 was Executive Vice President and Chief Financial Officer of Nabisco. From 1981 to 1996, Mr. Coughlin held various positions with Sterling Winthrop Incorporated, including Chief Financial Officer. Mr. Coughlin currently serves on the Board of Directors of Allergan plc. He previously served on the Board of Directors of Covidien (acquired by Medtronic), Actavis (which acquired Allergan), Dun & Bradstreet, Forest Laboratories (acquired by Actavis plc), Hologic, Inc., Dipexium Pharmaceuticals, Inc., The Interpublic Group of Companies, Monsanto Company, and Perrigo Company.

Mr. Coughlin received a bachelor's degree in accounting from Boston College.

Mr. Coughlin is Chair of the Audit and Finance Committee and a member of the Leadership and Compensation Committee.

   
Deborah Dunsire
Director

Deborah Dunsire has been a director of Alexion since January 2018. Dr. Dunsire served as President and Chief Executive Officer of Millennium Pharmaceuticals, Inc. from 2005-2013, where she led the transformation of the company into a biotechnology industry leader. Prior to Millennium, which became Takeda Oncology, Dr. Dunsire led the Novartis North America Oncology Business through a period of significant growth during her 10-year tenure. She also previously served as President and Chief Executive Officer of FORUM Pharmaceuticals and in a variety of R&D and Commercial positions with Sandoz AG. Dr. Dunsire currently serves as President and Chief Executive Officer of Xtuit Pharmaceuticals, Inc., a privately held biopharmaceutical company developing novel therapeutics.

Dr. Dunsire currently serves on the boards of Xtuit and Ultragenyx Pharmaceutical, Inc., a publicly traded biotechnology company. She previously served on the boards of Takeda Pharmaceuticals, Allergan, Inc., and FORUM Pharmaceuticals, Inc.

She received her medical degree from the University of Witwatersrand, Johannesburg, South Africa.

   
Paul A. Friedman M.D.
Director

Paul A. Friedman, M.D., has been a director of Alexion since September 2017. Dr. Friedman served as President and Chief Executive Officer of Incyte Corporation, a leading, publicly traded biopharmaceuticals company, from 2001-2014, where he led a transformation of the business from genomics to a therapeutic focus establishing its foundation as a leader in oncology. Currently, Dr. Friedman serves as Chairman and Chief Executive Officer of Madrigal Pharmaceuticals, Inc., following its merger with Synta Pharmaceuticals Corporation in July 2016. He has also held executive and R&D positions with DuPont Pharmaceuticals Research Laboratories, Merck Research Laboratories, and Merck Sharp & Dohme Corporation.

Dr. Friedman currently sits on the Board of Directors of Incyte Corporation and Madrigal Pharmaceuticals, Inc., both of which are publicly traded biotechnology companies. He previously served on the Board of Directors of Cerulean Pharma, Inc. and Verastem, Inc., both of which were publicly traded companies during Dr. Friedman's service.

Dr. Friedman received his M.D. from Harvard Medical School and his B.S. in Biology from Princeton University.

Dr. Friedman is a member of the Nominating and Corporate Governance Committee and the Science and Innovation Committee. 

   
John T. Mollen
Director

John T. Mollen has been a director of Alexion since April 2014. Mr. Mollen served as Executive Vice President, Human Resources (HR) of EMC Corporation from May 2006 until his retirement in February 2014, including two years as special advisor to the President. He joined EMC as Senior Vice President, Human Resources in September 1999. While at EMC, Mr. Mollen led the global human resources function to ensure the availability of world-class talent to drive business success and his responsibilities included executive, leadership, and employee development; compensation and benefits; staffing; and all of the people-related aspects of acquisition integration. Prior to joining EMC, Mr. Mollen was Vice President of Human Resources at Citigroup Inc. Mr. Mollen serves as a director for a number of not-for-profit and professional boards, including the New England Healthcare Institute, the HR Policy Association, Center on Executive Compensation, and as an advisory board member for Working Mother magazine and he is Chairman of the Board of Trustees of Worcester Polytechnic Institute.

Mr. Mollen received a bachelor's degree in economics from St. John Fisher College in Rochester, N.Y., and a master's degree in labor relations from St. Francis University in Loretto, Pa.

Mr. Mollen is Chair of the Leadership and Compensation Committee and a member of the Audit and Finance Committee.

   
Francois Nader M.D.
Director

Francois Nader, M.D., has been a director of Alexion since November 2017. Dr. Nader served as President, Chief Executive Officer, and Executive Director of NPS Pharma, a global biotechnology company that was focused on delivering innovative therapies to patients with rare diseases, from 2008 to 2015. Prior to NPS, Dr. Nader was a venture partner at Care Capital, a venture capital firm. He previously served on the North America Leadership Team of Aventis Pharma and its predecessor companies, holding a number of executive positions in integrated healthcare markets and medical and regulatory affairs. He also led global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. Dr. Nader currently serves as non-executive chairman of Acceleron Pharma, Inc. and on the boards of Clementia Pharmaceuticals Inc. and private company ArRETT Neuroscience.

Dr. Nader earned his French Doctorate in Medicine from St. Joseph University in Lebanon and a physician executive MBA from the University of Tennessee.

Dr. Nader is a member of the Audit and Finance Committee and the Science and Innovation Committee.

   
Judith A. Reinsdorf J.D.
Director

Judy Reinsdorf has been a director of Alexion since February 2018. Ms. Reinsdorf previously served as Executive Vice President and General Counsel of Johnson Controls International, a global leader in building products and technology, integrated solutions, and energy storage, following its merger in September 2016 with Tyco International, where she served as Executive Vice President and General Counsel from March 2007 until September 2016. Prior to Johnson Controls, Ms. Reinsdorf served as Vice President, General Counsel and Secretary of C. R. Bard, Inc., as Vice President and Corporate Secretary of Tyco, as Vice President and Associate General Counsel of Pharmacia Corporation, and as Assistant General Counsel and Chief Legal Counsel, Corporate, at Monsanto Company. She currently serves on the Board of Directors of Dun & Bradstreet, a publicly traded data and analytics company.

Ms. Reinsdorf earned her bachelor’s degree from the University of Rochester and her J.D. from Cornell Law School.

Ms. Reinsdorf is a member of the Audit and Finance Committee.

 

   
Andreas Rummelt, Ph.D.
Director

Dr. Andreas Rummelt has been a director of Alexion since February 2010. He has held executive management positions internationally for more than 20 years in the pharmaceutical industry, focused in the areas of manufacturing, quality and technical matters. He is currently the CEO and Partner of InterPharmaLink AG, a management consulting firm focused on advising companies in the healthcare industry. Dr. Rummelt was Group Head of Quality Assurance and Technical Operations at Novartis, and served as a member of the Executive Committee there. He also held various positions of increasing responsibility in development for Sandoz Pharma Ltd including CEO, Head of Worldwide Technical Research and Development, Head of Technical Operations of the Novartis Pharmaceuticals Division.

Dr. Rummelt earned his Ph.D. in Pharmaceutical Sciences from the University of Erlangen-Nuremberg, Germany. He received executive training in general management and leadership from IMD in Lausanne (Switzerland), INSEAD in Fontainebleau (France), and Harvard Business School in Cambridge (USA).

Dr. Rummelt is a member of the Nominating and Corporate Governance Committee and the Science and Innovation Committee.

   
= Chair of the Board
= Chair
= Member